Armenian Pharmaceutical Manufacturing Expands with $120M Investment

Armenia's pharmaceutical sector attracted $120 million in manufacturing investments during 2025, expanding domestic production capacity and positioning the country as a regional pharmaceutical hub.

Three new production facilities achieved GMP certification, enabling manufacturing of generic medications, antibiotics, and cardiovascular drugs for export to Eurasian Economic Union markets. Local pharmaceutical companies secured contracts worth $78 million.

The Ministry of Economy reports that domestic pharmaceutical production increased 58%, reducing Armenia's medication import dependency from 92% to 67%. Cost savings for the national healthcare system exceeded $34 million annually.

International pharmaceutical companies including Indian and Israeli firms established joint ventures with Armenian partners, transferring technology and training local specialists. Clinical trial activities expanded, with 12 new research programs initiated.

Government incentives provided tax holidays for pharmaceutical manufacturers and streamlined regulatory approval processes. The Armenian Drug and Medical Technology Agency reduced medication registration timelines from 18 to 8 months.

Export prospects improved significantly, with Armenian pharmaceutical products entering Russian, Georgian, and Uzbekistan markets. Industry projections suggest export revenues could reach $240 million by 2027.